Teen with terminal brain tumor fights for access to pioneering mRNA vaccine trial

Sixteen-year-old Coby Metzler was diagnosed with a diffuse midline glioma and given a 12-to-18-month prognosis. A novel personalized mRNA vaccine, PaedNeoVax (PTX-108), is slated for a world-first trial in Australia, but enrollment timing may exceed his remaining lifespan. His mother, Brigette Metzler, has mobilised legal, medical and community support, submitting a paper to decision-makers and pleading directly with Health Minister Mark Butler for emergency access.

The trial, overseen by Jordan Hansford of SAHMRI and Adelaide University and scientifically directed by Brandon Wainwright of the University of Queensland’s Frazer Institute and QIMR Berghofer, aims to test safety and dosage in pediatric oncology centres. Advocates such as Brain Tumour Alliance Australia and former pharma executive Oliver Jarrett argue for broader compassionate-use pathways and government funding, while the federal Department of Health notes that one outlet listing requires PBAC approval. The case highlights the tension between experimental promise and regulatory safeguards for children with terminal cancers.